Multi-dose-route, multi-species pharmacokinetic models for manganese and their use in risk assessment
Melvin E Andersen1, David C Dorman, Harvey J Clewell
1The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709-2137, USA.
Abstract:
Manganese (Mn) is an essential element that may be toxic in conditions of overexposure. Nearly 10 years ago, some of the authors of this article published a proposed methodology to perform a tissue-dose-based risk assessment and a detailed list of data needs necessary to perform the assessment. Since that time, a substantial body of Mn pharmacokinetic (PK) data has been generated in rats and nonhuman primates, allowing for the construction of physiologically based pharmacokinetic (PBPK) models for Mn. This study reviews the development of the Mn PBPK models, reassesses the previously identified data needs, and details potential uses of these models in risk assessment of Mn. Based upon numerous animal experiments, pharmacokinetic (PK) models have effectively simulated tissue kinetics of Mn from both inhaled and oral Mn intake. PK models achieve this by incorporating homeostatic control processes, saturable tissue binding capacities, and preferential fluxes in various tissue regions. While minor data gaps still exist, the models captured the main dose-dependent characteristics of Mn disposition in rodents and monkeys and provide a structure to parameterize an equivalent PK description in humans. These models are organized to contribute to a tissue-dose based risk assessment of Mn that simultaneously considers ingestion and inhalation kinetics of Mn along with homeostatic control of Mn.
Insights
Physiologically based pharmacokinetic (PBPK) models for manganese (Mn) have been developed using new animal data. These models simulate Mn tissue kinetics and aid in risk assessment for human overexposure.
Area of Science:
- Environmental toxicology
- Pharmacokinetics
- Risk assessment
Background:
- Manganese (Mn) is essential but toxic at high levels.
- Previous work proposed a methodology for Mn tissue-dose risk assessment.
- Significant new pharmacokinetic (PK) data in animal models has since been generated.
Purpose of the Study:
- To review the development of Mn physiologically based pharmacokinetic (PBPK) models.
- To reassess data requirements for Mn risk assessment.
- To detail the application of PBPK models in Mn risk assessment.
Main Methods:
- Development of PBPK models for Mn using extensive animal PK data.
- Incorporation of homeostatic control, saturable binding, and tissue-specific fluxes.
- Simulation of Mn tissue kinetics from both inhalation and oral intake.
Main Results:
- PBPK models effectively simulate Mn tissue kinetics in rodents and nonhuman primates.
- Models capture dose-dependent Mn disposition characteristics.
- Minor data gaps remain, but models provide a framework for human PK description.
Conclusions:
- Developed Mn PBPK models are valuable tools for risk assessment.
- Models integrate ingestion and inhalation kinetics with Mn homeostatic control.
- These PBPK models advance the goal of tissue-dose based risk assessment for Mn.
Related Concept Videos
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Multicompartment Models: Overview
These models offer a more comprehensive representation of drug behavior in the body than one-compartment models. They accommodate the complexity of drug distribution,...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Model Approaches for Pharmacokinetic Data: Compartment Models
Two primary types of compartment models are recognized: mammillary and catenary. The more...


